Indication
Kaposiform Hemangioendothelioma
6 clinical trials
4 products
1 drug
Clinical trial
Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma:a Randomized Controlled StudyStatus: Recruiting, Estimated PCD: 2024-08-30
Product
TacrolimusClinical trial
Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma: a Randomized Controlled TrialStatus: Completed, Estimated PCD: 2023-02-01
Product
SirolimusClinical trial
A Randomized Phase 2 Study of Vincristine Versus Sirolimus to Treat High Risk Kaposiform Hemangioendothelioma (KHE).Status: Terminated, Estimated PCD: 2019-10-02
Drug
VincristineClinical trial
Efficacy and Safety of High- vs Low-Dose Sirolimus in Patients With Kaposiform Hemangioendothelioma: A Trial ProtocolStatus: Completed, Estimated PCD: 2023-08-10
Clinical trial
Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies: a Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma:A Prospective, Randomized Open TrialStatus: Completed, Estimated PCD: 2022-12-10
Product
Sirolimus(0.8mg/m2)Product
Sirolimus(0.7mg/m2)